Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tivantinib behaves as an antimitotic agent.

Published byCody Butler Modified over 5 years ago

Similar presentations

Presentation on theme: "Tivantinib behaves as an antimitotic agent."— Presentation transcript:

1 Tivantinib behaves as an antimitotic agent.
Tivantinib behaves as an antimitotic agent. A, Scatter plots showing correlations between sensitivity patterns assessed by the AUC of two antimitotic drugs (paclitaxel and vinblastine) and tivantinib among 35 liver cancer cell lines. B, Effect of tivantinib on the mitotic index was compared with the antimitotic drugs paclitaxel and vinblastine after overnight treatment of the HLE cell line with two different concentrations of each drug. Sandra Rebouissou et al. Clin Cancer Res 2017;23: ©2017 by American Association for Cancer Research

Download ppt "Tivantinib behaves as an antimitotic agent."

Similar presentations

Genomic signatures to guide the use of chemotherapeutics Authors: Anil Potti et. al Presenter: Jong Cheol Jeong.

Genomic signatures to guide the use of chemotherapeutics Authors: Anil Potti et. al Presenter: Jong Cheol Jeong.
IDH1 mutant glioma cells are sensitive to TMZ

IDH1 mutant glioma cells are sensitive to TMZ
Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 2 The association between CD8+ T‑cell density of the tumour
Figure 3 Drug cycling with collateral sensitivity

Figure 3 Drug cycling with collateral sensitivity
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.
PTENP1 sensitizes renal cancer cells to chemotherapy.

PTENP1 sensitizes renal cancer cells to chemotherapy.
Protein expression profile in a dasatinib-resistant cell line.

Protein expression profile in a dasatinib-resistant cell line.
Β-Cryptoxanthin at a concentration of 10 μmol/L decreases proliferation in HCT116 cells after 6 and 8 days of treatment. β-Cryptoxanthin at a concentration.

Β-Cryptoxanthin at a concentration of 10 μmol/L decreases proliferation in HCT116 cells after 6 and 8 days of treatment. β-Cryptoxanthin at a concentration.
Binding and internalization of bispecific immunotoxins.

Binding and internalization of bispecific immunotoxins.
Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.
Vascular staining in CWR22R xenograft tumors.

Vascular staining in CWR22R xenograft tumors.
A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.

A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.
Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases. Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases.

Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases. Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases.
MiR-200c is a PI3K–AKT signaling pathway regulator in CRC

MiR-200c is a PI3K–AKT signaling pathway regulator in CRC
Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.
A, RT-PCR expression of matriptase-1 and matriptase-2 in a variety of 24 human cell lines. A, RT-PCR expression of matriptase-1 and matriptase-2 in a variety.

A, RT-PCR expression of matriptase-1 and matriptase-2 in a variety of 24 human cell lines. A, RT-PCR expression of matriptase-1 and matriptase-2 in a variety.
A, the effect of rh-Matrilysin (100 units/ml) or HGF/SF (60 ng/ml) on colony scattering in LNCapFGC cells after incubation at 37°C for up to 7 h. A, the.

A, the effect of rh-Matrilysin (100 units/ml) or HGF/SF (60 ng/ml) on colony scattering in LNCapFGC cells after incubation at 37°C for up to 7 h. A, the.
ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.
Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Similar presentations

Ads by Google